1. Scrip
  2. >>Business

Tech Transfer Roundup: J&J Houses JPOD Incubator At University Of Pennsylvania

 
• By Joseph Haas

Pascal and Oblato separately license therapeutic candidates for glioblastoma multiforme, while Cabaletta emerges from UPenn with novel program for CAAR-T therapies in B-cell mediated autoimmune disease.

Pennovation Center, PA
JPOD @ Philadelphia Is Housed At Pennovation Center

[Johnson & Johnson Innovation - JLABS] has been launching its JLABS sites within biotechnology hubs such as Boston, San Diego and San Francisco since 2012, but it chose Philadelphia as the site for its initial JPOD in the US, in part to capitalize on its strong partnership with the University of Pennsylvania and its two-year-old incubator, the Pennovation Center, which will house the JPOD.

The Philadephia area is also an innovation hotspot, JLABS Head Kate Merton told Scrip, making it a prime location as...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Finance Watch: Just As The XBI Began Turnaround, Trump Upped MFN Pricing Threats

 
• By Mandy Jackson

Public Company Edition: The XBI fund attempted a correction midway through the week ending Aug. 1, but President Trump’s most favored nation drug pricing threats tanked valuations again. In financings, Leads Biolabs raised $189m in a Hong Kong IPO and Abivax closed a $747.5m FOPO.

Regulatory Setbacks Dim Otherwise Strong Quarter For Regeneron

 
• By Alaric DeArment

Eylea HD saw significant sales growth, but the company reported delays in FDA approvals for the drug and a CRL for its CD20xCD3-targeting bispecific for lymphomas.

Metabolic Disease-Focused Poxel Teeters On The Edge

 
• By Andrew McConaghie

The Lyon, France-based company has filed for insolvency and is running out of time to find new funding for its metabolic disease pipeline.

UCB Takes A Bow as Bimzelx HS Launch Achieves Lift-Off

 
• By Manas Mishra

The Belgian company has raised its outlook for full-year sales following a strong launch for Bimzelx in hidradenitis suppurativa in the first half of 2025.

More from Scrip

Most Favored Nation Pricing: Trump Ups Pressure On Voluntary Action, Clarifies Demands

 
• By Sarah Karlin-Smith

The new 60-day deadline for striking a deal with the drug industry underscores the challenges the Administration may be having in developing non-voluntary policies to achieve MFN pricing in the US.

Multiple Factors Driving Japan’s Pioneering Angiosarcoma Pipeline

 
• By Lisa Takagi

Japan has emerged as a global leader in the development of new drugs for the rare cancer angiosarcoma, reflecting its rapidly ageing population and the limitations of current therapies.

Bristol’s Q2 Earnings Homerun Overshadowed By Clinical Trial Review Curveball

 
• By Mandy Jackson

Second quarter revenue and EPS beat consensus and BMS raised its 2025 revenue guidance, but after multiple recent Phase III failures, executives said the company is reviewing studies with near-term readouts.